



Testing Taskforce: New California COVID-19 cases, hospitalizations and deaths


Cases per 100K



14 day average Hospitalizations



7 day Average Deaths



Average test positivity past 7 days 5%, Down 1.0% from last week

Cases have fallen from the peak, test positivity remains moderately high

14 day average hospitalizations have started to decline but are about 2.5 times the previous level

7 day average deaths remain at low levels.

For the week ending 9/17, 91% of molecular tests resulted in 24 hours and 97% of tests resulted in less than 48 hours.

Sept 22, 2022 with data as of Sept 20, 2022.

<https://covid19.ca.gov/state-dashboard/> <https://testing.covid19.ca.gov/>
COVID-19 Cases Dashboard v2.0 - CA Open Data | Tableau Pub

Variant update

- BA.5: US 83.1%, California 90.8%
- In the US and worldwide, BA.5 resulted in a surge of cases and hospitalizations and now in most places around the world cases and hospitalizations are declining. Cases are beginning to rise again in France and Germany. Rises in cases in Europe have often preceded rising cases in the US.
- In the US there has been a rise in deaths to ~500/day up from a prior baseline of ~250/day.
- The FDA has not reported any new failures to testing for antigen tests or molecular tests with BA.4/ BA.5.

BA.4.6

- Defining spike mutation = **S:R346T**
- Mutation at this position within spike previously associated with immune escape
- Growth advantage approximately 16-21% over BA.5
- Most of BA4.6 cases are in the Midwest and Northeast
- Currently 11.9% of cases in the US and 4.7% of cases in California, this has increased somewhat from two weeks ago.

BA.2.75 and BA.2.75.2

- First detected in India, cases of BA2.75 are rising there, and it is outcompeting BA5
- BA.2.75 has multiple mutations in the spike protein of the virus which may increase infectivity and may evade the immune system. Estimated 5% growth advantage over BA.5
- Daughter strain BA.2.75.2 has a 10% growth advantage and is emerging in California
- BA.2.75 California: 1.7% of sequenced cases
- US 1.4% of sequenced cases
- We are watching this closely

BQ.1, BA.2.3.20, BF.7

- BQ.1 (daughter of BA.5) 15% growth advantage over BA.5, first reported in the UK, At least 3 cases in California
- BA.2.3.20 15% growth advantage over BA.5, at least 6 cases in California
- BF.7 (BA.5.2.1.7),
 - US: 2.3%
 - California 1.1%, cases are rising

Convergent mutations in different strains

- Noticing similar mutations in the emerging strains across lineages that confer fitness advantage

Paxlovid Resistance Currently Not Seen

- Currently we are **NOT** seeing signs of mutations in SARS-CoV-2 likely to impact the effectiveness of Paxlovid
- We are monitoring the genomic sequencing data for known Paxlovid resistance mutations